160 related articles for article (PubMed ID: 16421119)
1. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis.
Kanesaka T; Mori M; Hattori T; Oki T; Kuwabara S
J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):185-8. PubMed ID: 16421119
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.
Galboiz Y; Shapiro S; Lahat N; Rawashdeh H; Miller A
Ann Neurol; 2001 Oct; 50(4):443-51. PubMed ID: 11601495
[TBL] [Abstract][Full Text] [Related]
4. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis.
Liuzzi GM; Trojano M; Fanelli M; Avolio C; Fasano A; Livrea P; Riccio P
Mult Scler; 2002 May; 8(3):222-8. PubMed ID: 12120694
[TBL] [Abstract][Full Text] [Related]
7. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.
Karabudak R; Kurne A; Guc D; Sengelen M; Canpinar H; Kansu E
J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006
[TBL] [Abstract][Full Text] [Related]
8. TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis.
Trentini A; Manfrinato MC; Castellazzi M; Tamborino C; Roversi G; Volta CA; Baldi E; Tola MR; Granieri E; Dallocchio F; Bellini T; Fainardi E;
Mult Scler; 2015 Aug; 21(9):1121-30. PubMed ID: 25662349
[TBL] [Abstract][Full Text] [Related]
9. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
[TBL] [Abstract][Full Text] [Related]
11. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Trojano M; Avolio C; Liuzzi GM; Ruggieri M; Defazio G; Liguori M; Santacroce MP; Paolicelli D; Giuliani F; Riccio P; Livrea P
Neurology; 1999 Oct; 53(7):1402-8. PubMed ID: 10534242
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
13. Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology.
Thrailkill KM; Moreau CS; Cockrell G; Simpson P; Goel R; North P; Fowlkes JL; Bunn RC
Clin Chem Lab Med; 2005; 43(12):1392-9. PubMed ID: 16309379
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
15. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Tamborino C; Trentini A; Manfrinato MC; Baldi E; Tola MR; Dallocchio F; Granieri E; Bellini T
Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
[TBL] [Abstract][Full Text] [Related]
16. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
Comabella M; Río J; Espejo C; Ruiz de Villa M; Al-Zayat H; Nos C; Deisenhammer F; Baranzini SE; Nonell L; López C; Julià E; Oksenberg JR; Montalban X
Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis.
Yılmaz Ü; Gücüyener K; Atak A; Aral A; Gürkaş E; Demir E; Serdaroğlu A
Pediatr Neurol; 2012 Sep; 47(3):171-6. PubMed ID: 22883281
[TBL] [Abstract][Full Text] [Related]
18. Proteolytic balance in patients with multiple sclerosis during interferon treatment.
Giannelli G; De Marzo A; Scagnolari C; Bergamini C; Fransvea E; Bagnato F; Bellomi F; Millefiorini E; Gasperini C; Antonaci S; Antonelli G
J Interferon Cytokine Res; 2002 Jun; 22(6):689-92. PubMed ID: 12162880
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
20. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
Bernal F; Elias B; Hartung HP; Kieseier BC
Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
